Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter intravenous golimumab study in children with active polyarticular juvenile idiopathic arthritis despite methotrexate
MOH_2017-07-12_000622Phase 3Recruiting
- Sponsor
- Janssen Research & Development
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of golimumab in juvenile idiopathic arthritis (JIA), sponsored by Janssen Research & Development. Primary endpoints: Pharmacokinetics of intravenous golimumab, Efficacy of intravenous golimumab and 1 more. Started Jul 2015; status: recruiting.
02
Drugs
golimumab
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on MOH_2017-07-12_000622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-12_000622.